Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/63013
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification
Author: Schroth, W.
Hamann, U.
Fasching, P.
Dauser, S.
Winter, S.
Eichelbaum, M.
Schwab, M.
Brauch, H.
Citation: Clinical Cancer Research, 2010; 16(17):4468-4477
Publisher: Amer Assoc Cancer Research
Issue Date: 2010
ISSN: 1078-0432
1557-3265
Statement of
Responsibility: 
Werner Schroth, Ute Hamann, Peter A. Fasching, Silke Dauser, Stefan Winter, Michel Eichelbaum, Matthias Schwab, and Hiltrud Brauch
Abstract: PURPOSE: This study aimed to validate matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS)/Taqman copy number assay (CNA) CYP2D6 genotyping by AmpliChip CYP450 Test for the prediction of tamoxifen metabolizer phenotypes in breast cancer, and to investigate the influence of CYP2D6 variant coverage on genotype-phenotype relationships and tamoxifen outcome. EXPERIMENTAL DESIGN: Hormone receptor-positive postmenopausal breast cancer patients (n = 492) treated with adjuvant tamoxifen, previously analyzed by MALDI-TOF MS/CNA, were reanalyzed by AmpliChip CYP450 Test and validated by independent methods. Cox proportional hazard ratios (HR) were calculated for recurrence of poor (PM) relative to extensive metabolizer (EM) phenotypes with increasing numbers of CYP2D6 variants. Kaplan-Meier distributions were calculated for different phenotype classifications. RESULTS: Concordance was 99.2% to 99.5% for CNA and 99.8% to 100% per CYP2D6 allele (*3, *4, *5, *9, *10, and *41). The prevalence of predicted phenotypes was 1.2% for ultrarapid metabolizer (UM), 37.2% for EM without variant, 43.5% for heterozygous EM, 9.7% for intermediate metabolizer (IM), and 8.3% for PM. Approximately, one third of patients were misclassified based on a *4 analysis only, but inclusion of all reduced-function alleles increased the PM-associated HR from 1.33 (P = 0.58) to 2.87 (P = 0.006). Kaplan-Meier analyses showed highest and lowest clinical benefit for UM and PM with respect to both the AmpliChip-based and a redefined phenotype assignment. The latter revealed significant allele-dose-dependent associations (P = 0.011) and largest effect size (HR(PM_EM) = 2.77; 95% confidence interval, 1.31-5.89). CONCLUSIONS: MALDI-TOF MS/CNA is suitable for accurate CYP2D6 genotyping. For tamoxifen pharmacogenetics, broad CYP2D6 allele coverage is recommended to reduce phenotype misclassification. Classification based on refined EM and reduced-function metabolizers is advisable. AACR.
Keywords: Humans; Breast Neoplasms; Tamoxifen; Cytochrome P-450 CYP2D6; Antineoplastic Agents, Hormonal; Prognosis; Treatment Outcome; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Proportional Hazards Models; Risk Assessment; Retrospective Studies; Genotype; Gene Dosage; Phenotype; Polymorphism, Genetic; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Kaplan-Meier Estimate
Rights: © 2010 American Association for Cancer Research.
RMID: 0020102518
DOI: 10.1158/1078-0432.CCR-10-0478
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.